Skip to main content
Premium Trial:

Request an Annual Quote

Proteros Fragments, Axikin Reach Milestones in Drug-discovery and -development for COPD

Premium

This story originally ran on Feb. 25.

Proteros Fragments and Axikin Pharmaceuticals this week said they have reached "significant milestones" in their drug-discovery collaboration.

The two firms have made "rapid progress" in the discovery and characterization of distinct chemical entities toward a novel therapeutic target for chronic obstructive pulmonary disease, the companies said in a joint statement.

In the first phase of the partnership, Proteros Fragments, using its X-ray crystallography platform, solved a de novo X-ray crystallographic structure of a protein targeted by Axikin. The company also developed a selective assay and screened its proprietary library of about 20,000 distinct novel fragments.

The fragment screen revealed hits from a number of distinct different chemotypes that bind to the active site of the target protein, whose identity was not disclosed. Each of the chemotypes has been validated, the companies said, and the binding mode was determined by X-ray crystallography "to develop the most promising candidate for subsequent fragment evolution, lead finding, and optimization."

Their collaboration, forged last April, is to discover lead compounds for inflammatory diseases. Under the terms of the deal, Proteros Fragments, headquartered in Martinsried, Germany, will provide research aimed at generating candidate leads for inhibiting a novel proprietary target protein [See PM 04/02/09].

Proteros Fragments was founded in the summer of 2008 as a subsidiary of Proteros Biostructures and offers services centered on the discovery of fragment-based lead structures.

Axikin is based in San Diego.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.